NCT06074029进行中（未招募）1 期
Exploratory Study on the Therapeutic Effect Prediction Model of Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
- Establish a predictive model for the efficacy of immune checkpoint inhibitors (ICI) in Chinese patients with biliary tract cancers. By analyzing the dynamic changes of circulating tumor DNA (ctDNA) and other clinical and pathological features before and after ICI treatment in a cohort of patients with biliary tract tumors, a predictive model can be established to evaluate the efficacy of ICI treatment in the early stages or even before treatment, serving as a reliable tool for selecting patients who are likely to benefit from ICI treatment.
- Investigate the clinical features of populations that benefit from different immune combination therapies. By comparing the differences and enrichment of mutations between patients receiving different treatment regimens, and if patients have sufficient pre-treatment tissue, further comparisons of differentially expressed genes and pathways may be made.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subjects voluntarily participate in the study and agree to sign the informed consent form, are compliant, and cooperate with follow-up.
- •Patients with advanced biliary tract cancers (including gallbladder cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma, or distal cholangiocarcinoma) with histologically, cytologically, or clinically confirmed.
- •Patients who have undergone curative surgery and experienced disease recurrence after more than 6 months; or patients who have completed adjuvant therapy (chemotherapy and/or radiotherapy) and have been disease-free for more than 6 months after completing adjuvant therapy are eligible for inclusion.
- •Regardless of gender, age 18-80 years old.
- •ECOG PS of 0-2 with expected survival time ≥12 weeks.
- •According to RECIST V1.1, the patient had at least one measurable lesion.
- •The patient is suitable for treatment with immune checkpoint inhibitors (PD-1/PD-L1 inhibitor).
排除标准
- •Suffering from other malignant tumors.
- •Previous systemic treatment received.
- •Patients with serious organic diseases cannot receive the treatment designed in this study;
- •Having a psychiatric disorder does not guarantee compliance with this study.
- •Patients with symptomatic brain metastasis or complications related to brain metastasis or cognitive impairment.
- •Adverse events (except hair loss of any grade) from previous antitumor therapy did not return to ≤ grade 1 or better (According to CTCAE version 5.0).
- •Previously received any cell or organ transplant treatment.
- •Allergy to the therapeutic drugs of this study or CT or MRI-enhanced contrast agents.
- •Received local hepatobiliary treatment (including various types of ablations, percutaneous ethanol or acetic acid injection, high-intensity focused ultrasound, transarterial embolization, chemotherapy, or chemoembolization) within 14 days before the start of the study treatment.
- •The physician determines that there are any contraindications to ICI treatment.
- •During the second blood monitoring, the disease changes could not be judged (such as unexplained ascites, worsening symptoms); Or non-disease progression, but the next immunotherapy is not planned.
研究组 & 干预措施
Immunotherapy cohort
Experimental
Patients who were administered with immunotherapy
干预措施: Immune Checkpoint Inhibitors (Drug)
结局指标
主要结局
Progression free survival
时间窗: Baseline up to approximately 12 months
It refers to the time from the first administration of the regimen to the first occurrence of disease progression or death due to any cause in the subjects.
次要结局
- Overall survival(Baseline up to approximately 15 months)
- Objective response rate(Baseline up to approximately 6 months)
- Time to treatment discontinuation(Baseline up to approximately 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological TypeUncommon Pathological Types of Lung CancerNCT05023837Hunan Province Tumor Hospital40
招募中
不适用
First-Line and Neoadjuvant Immunotherapy for Gastric CancerAdvanced Gastric CancerLocally Advanced Gastric CarcinomaNCT06727981Qilu Hospital of Shandong University500
终止
2 期
Immunotherapy Study for Patients With Stage IV MelanomaStage IV MelanomaMetastatic MelanomaNCT02054520NewLink Genetics Corporation47
已完成
不适用
Immune Checkpoint Inhibitors and Atherosclerotic Plaque VolumeNon-small Cell Lung CancerNCT04430712Massachusetts General Hospital60
撤回
不适用
Personalizing Immune Checkpoint Inhibitor TherapyLung Cancer Stage IVNCT03409341Holy Cross Hospital, Maryland